1. United States Food and Drug Administration.OZEMPIC (semaglutide) injection for subcutaneous use.https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/209637s003lbl.pdf
2. European Medicines Agency.Ozempic: summary of product characteristics.https://www.ema.europa.eu/en/documents/product-information/ozempic-epar-product-information_en.pdf
3. Novo Nordisk.Wegovy. Semaglutide injection 2.4 mg.https://www.novo-pi.com/wegovy.pdf
4. Novo Nordisk.Wegovy. Summary of product characteristics.https://www.ema.europa.eu/en/documents/product-information/wegovy-epar-product-information_en.pdf
5. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy inJapanese people with type 2 diabetes